Scorpius Holdings commends congress on bipartisan legislative action

Scorpius Holdings applauded on-going legislative efforts within the United States Congress to bolster domestic biomanufacturing in the face of vulnerabilities from America’s adversaries. The most notable legislative effort is the recent introduction of the BIOSECURE Act, which would mark a significant step forward in strengthening America’s pharmaceutical supply chain and reducing dependency on foreign manufacturers. The BIOSECURE Act is now seeing significant bipartisan momentum in Congress, advancing out of the House Oversight Committee this week, setting the stage for a possible vote and final passage by the end of the year. Other notable efforts include recent legislative and policy measures that prioritize U.S. Government investment and development for U.S.-based biomanufacturing, as well as the launch of the BioMaP Consortium within the Biomedical Advanced Research and Development Authority, of which Scorpius is a member.